Cancer

Cancer

Cadonilimab Demonstrates Manageable Toxicity and Promising Efficacy in Heavily Pretreated Solid Tumor Patients

Researchers at Peking University Third Hospital have conducted a phase 1b study to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with cadonilimab, a humanized immunoglobulin G1 bispecific antibody targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). The study involved 63 patients